Table 1.
Open clinical trials exploring the role of immune-checkpoint blockade with CAR-T cell therapy.
| Clinical Trials.gov Identifier (ref.) | CAR-T (Trial Nickname) | Blockade of PD-1 Axis | Target Disease | Sponsor |
|---|---|---|---|---|
| NCT02706405 | JCAR014 | Durvalumab; on D28 + up to 10 doses, every 4 weeks or on D-1 and -28 (and additional dose allowed) |
DLBCL, double-hit lymphoma, PMBL, tDLBCL | Fred Hutchinson Cancer Research Center |
| NCT03310619 | JCAR017 (PLATFORM) | Durvalumab; Dose/schedule: NA |
Aggressive B-NHL | Celgene |
| NCT02926833 [48] | KTE-C19 (ZUMA-6) | Atezolizumab; 4 doses every 3 weeks from D1, D14 or D21 in each cohort |
DLBCL | Kite pharma |
| NCT03287817 | CD19/22 CAR-T (ALEXANDER) | Pembrolizumab as consolidation Dose/schedule: NA |
DLBCL | Autolus limited |
| NCT02650999 * | CTL019 | Pembrolizumab; every 3 weeks up to 18 doses |
CD19+ DLBCL, FL, MCL | University of Pennsylvania |
Abbreviations: B-NHL, B-cell non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PMBL, primary mediastinal large B-cell lymphoma; tDLBCL, transformed diffuse large B-cell lymphoma. * Phase I/II study of pembrolizumab in patients failing after CD19-specific CAR-T cell therapy for relapsed or refractory CD19+ non-Hodgkin lymphoma. The trial does not aim to study the combination of CAR-T and PD-1 blockade but the role of salvage therapy of pembrolizumab in patients whose disease progressed after CTL019.